Home/Ideas/International Quality ADRs: Best-in-Class Companies Outside the US

International Quality ADRs: Best-in-Class Companies Outside the US

Investment IdeasData as of 2026-03-14
US-listed ADRs of international quality companies trading at meaningful valuation discounts to US peers. Global diversification with quality metrics that match or exceed domestic equivalents.

The best companies in the world are not all American. ASML, Novo Nordisk, and TSMC would be top holdings in any quality portfolio.

Stoquity AI Committee
Countries
6+
Avg P/E Discount
-25%
Avg Quality Score
88
Stocks
5

1Theme Overview

International stocks have underperformed US equities for 15+ years, creating a historic valuation gap. International markets trade at 13x forward earnings versus 22x for the US. Many world-class companies outside the US offer comparable quality at lower prices.

2Why Now?

Dollar strength appears to be peaking, which historically triggers international outperformance. European and Asian companies are improving corporate governance and increasing shareholder returns (buybacks, dividends). The valuation gap is at its widest in decades.

3Screening Methodology

Screen for US-listed ADRs of international companies scoring in the top quintile on quality, trading at valuation discounts to US sector peers.

Filter Criteria
US-listed ADR, quality score top 20%, forward P/E below US sector median, market cap > $50B, Stoquity composite > 79.

Factors used: QualityProfitabilityValueRevenue GrowthCash Flow

4Top Picks (5 Stocks)

ASML — ASML Holding
Semiconductors Score: 92
Market Cap: $350B
Quality
96
Profitability
94
Revenue Growth
86

Thesis: Monopoly supplier of EUV lithography systems essential for advanced chip manufacturing. $40B+ backlog with 50%+ gross margins. Every leading chipmaker (TSMC, Samsung, Intel) is a customer.

Risks: China export restrictions limit addressable market; cyclical semiconductor capex; geopolitical tension affecting European companies.

NVO — Novo Nordisk
Healthcare Score: 90
Market Cap: $430B
Quality
94
Revenue Growth
92
Profitability
90

Thesis: Global GLP-1 leader with Ozempic and Wegovy dominating diabetes and obesity markets. Revenue growing 30%+ driven by weight-loss drug demand. Manufacturing expansion underway to address supply constraints.

Risks: GLP-1 competition from Eli Lilly; manufacturing capacity bottlenecks; potential regulatory price controls outside US.

SAP — SAP SE
Software Score: 86
Market Cap: $290B
Quality
90
Revenue Growth
84
Profitability
82

Thesis: Enterprise software leader with 80%+ of Fortune 500 as customers. Cloud transition driving recurring revenue above 80%. S/4HANA migration cycle extends through 2027+.

Risks: Cloud transition margin dilution; long migration cycles create execution risk; competition from Oracle and Workday.

SHOP — Shopify (Canadian)
Technology Score: 84
Market Cap: $120B
Revenue Growth
88
Momentum
85
Quality
82

Thesis: Leading e-commerce platform powering 10%+ of US e-commerce. Merchant solutions (payments, shipping, capital) driving revenue diversification. Enterprise upmarket push gaining traction.

Risks: E-commerce growth normalization; competition from Amazon; merchant churn in economic downturns.

TM — Toyota Motor
Automotive Score: 80
Market Cap: $260B
Value
90
Quality
85
Cash Flow
84

Thesis: World's largest automaker by volume. Hybrid strategy proving prescient as EV growth slows. Trading at 9x earnings with record profitability. Balance sheet holds $50B+ net cash.

Risks: Yen appreciation compresses export profitability; EV transition uncertainty; governance reforms under pressure.

View compact comparison table
SymbolNameSectorScoreMarket Cap
ASMLASML HoldingSemiconductors92$350B
NVONovo NordiskHealthcare90$430B
SAPSAP SESoftware86$290B
SHOPShopify (Canadian)Technology84$120B
TMToyota MotorAutomotive80$260B

5Theme Risks

International investing adds currency risk, geopolitical risk, and potentially different accounting standards. ADRs can trade at premiums/discounts to local shares. Many international markets have structural growth headwinds (demographics, regulation).

💡 Did You Know?

Non-US stocks trade at a 30%+ P/E discount to US equities despite similar quality metrics — the widest valuation gap in 20 years.

This content is for informational and educational purposes only. It is not a recommendation to buy, sell, or hold any security. Stoquity is not a registered investment advisor. Past performance does not guarantee future results. All investment involves risk, including loss of principal. Stock scores, factor breakdowns, and performance data are generated by Stoquity's AI-powered scoring model and should not be the sole basis for investment decisions. Always conduct your own research and consider consulting a licensed financial professional.

Screen stocks yourself

Use the same 24-factor scoring model that powers Stoquity portfolios.

Try the AI Screener →